296 related articles for article (PubMed ID: 30779070)
21. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
[TBL] [Abstract][Full Text] [Related]
22. Scutellarin inhibits proliferation and invasion of hepatocellular carcinoma cells via down-regulation of JAK2/STAT3 pathway.
Liu K; Tian T; Zheng Y; Zhou L; Dai C; Wang M; Lin S; Deng Y; Hao Q; Zhai Z; Dai Z
J Cell Mol Med; 2019 Apr; 23(4):3040-3044. PubMed ID: 30697962
[TBL] [Abstract][Full Text] [Related]
23. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma.
Lin J; Cao S; Wang Y; Hu Y; Liu H; Li J; Chen J; Li P; Liu J; Wang Q; Zheng L
J Exp Clin Cancer Res; 2018 Jun; 37(1):113. PubMed ID: 29866133
[TBL] [Abstract][Full Text] [Related]
25. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
Ding H; Zhang X; Su Y; Jia C; Dai C
Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP).
Tang C; Feng W; Bao Y; Du H
Bioengineered; 2021 Dec; 12(1):2119-2131. PubMed ID: 34057016
[TBL] [Abstract][Full Text] [Related]
27. Propofol induces hepatocellular carcinoma cell apoptosis via regulating miR-105/JAK2/STAT3 axis.
Li J; Liu M; Zeng B; Wang Z
Cytokine; 2021 Dec; 148():155649. PubMed ID: 34388478
[TBL] [Abstract][Full Text] [Related]
28. LncRNA RUNX1-IT1 inhibits proliferation and promotes apoptosis of hepatocellular carcinoma by regulating MAPK pathways.
Yan PH; Wang L; Chen H; Yu FQ; Guo L; Liu Y; Zhang WJ; Bai YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8287-8294. PubMed ID: 31646558
[TBL] [Abstract][Full Text] [Related]
29. Long Noncoding RNA AK021443 Promotes Cell Proliferation and Migration by Regulating Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.
Yang J; Li J; Liu B; Zhang R; Gu F; Zhao J; Cheng S
DNA Cell Biol; 2018 May; 37(5):481-490. PubMed ID: 29638164
[TBL] [Abstract][Full Text] [Related]
30. LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2.
Jin L; He Y; Tang S; Huang S
J Cell Physiol; 2018 Jun; 233(6):4726-4734. PubMed ID: 29139562
[TBL] [Abstract][Full Text] [Related]
31. LINC00346 promotes hepatocellular carcinoma progression via activating the JAK-STAT3 signaling pathway.
Yin YZ; Zheng WH; Zhang X; Chen YH; Tuo YH
J Cell Biochem; 2020 Jan; 121(1):735-742. PubMed ID: 31478228
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma.
Liu T; Shi Q; Yang L; Wang S; Song H; Wang Z; Xu X; Liu H; Zheng H; Shen Z
BMC Cancer; 2021 Aug; 21(1):957. PubMed ID: 34445994
[TBL] [Abstract][Full Text] [Related]
33. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT.
Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354
[TBL] [Abstract][Full Text] [Related]
34. lncRNA HOXB-AS3 promotes hepatoma by inhibiting p53 expression.
Zhang XM; Chen H; Zhou B; Zhang QY; Liao Y; Wang JS; Wang ZH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6784-6792. PubMed ID: 30402841
[TBL] [Abstract][Full Text] [Related]
35. TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma.
Yin YT; Shi L; Wu C; Zhang MY; Li JX; Zhou YF; Wang SC; Wang HY; Mai SJ
Med Oncol; 2024 Feb; 41(3):79. PubMed ID: 38393440
[TBL] [Abstract][Full Text] [Related]
36. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma.
Pan L; Xiao H; Liao R; Chen Q; Peng C; Zhang Y; Mu T; Wu Z
Biomed Pharmacother; 2018 Oct; 106():68-76. PubMed ID: 29957468
[TBL] [Abstract][Full Text] [Related]
37. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
38. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
Ma CX; Gao WC; Tian L
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
[TBL] [Abstract][Full Text] [Related]
39. PHD2 acts as an oncogene through activation of Ras/Raf/MEK/ERK and JAK1/STAT3 pathways in human hepatocellular carcinoma cells.
Guo J; Lan Z
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):37-45. PubMed ID: 31852247
[No Abstract] [Full Text] [Related]
40. LncRNA SBF2-AS1 promotes hepatocellular carcinoma metastasis by regulating EMT and predicts unfavorable prognosis.
Zhang YT; Li BP; Zhang B; Ma P; Wu QL; Ming L; Xie LM
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6333-6341. PubMed ID: 30338801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
